-
ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers
ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers.
-
Synpromics raises £5.2m of new investment
Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce that it has completed a financing round of £5.2M.
-
The RSA Group appoints Shawn O’Connor as Partner in New Jersey
The RSA Group, a leading Life Sciences executive search firm, is pleased to announce the appointment of Shawn O’Connor as Partner.
-
BioCity makes FT 1000 list of Europe’s fastest growing companies
Nottingham, UK, 10th April 2017 / Sciad Newswire / Biocity Group (BioCity), the UK’s largest bioscience incubator, which this week celebrated the handover of the new Discovery Building at their Nottingham headquarters, has been identified as one of Europe’s fastest growing companies by the Financial Times’ FT 1000 report. This was the first time that the FT, in partnership with…
-
ATUM Launches Cell-Line Development Service
ATUM has announced an expansion of its services to include cell line development, enabled by their proprietary Leap-In Transposase genome engineering tools.
-
Nuclear architecture emerges at the awakening of the genome
Munich, Germany, 6th April 2017 / Sciad Newswire / Max Planck scientists unravel when during development the 3D organisation of the genome in the nucleus arises. Their finding, published in Cell, reveals that the genome first takes its proper shape when transcription is first turned on in the zygote. Transcription itself however is not required for this process. The DNA molecules in each…
-
Matt Vossler joins The RSA Group as Partner in North America
The RSA Group, a leading Life Sciences executive search firm, is pleased to announce the appointment of Matt Vossler as Partner.
-
Oppilotech Secures Funding From CARB-X to Fight Drug Resistant Infections
Oppilotech announced today it has been selected for funding by a new public-private partnership – The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator.
-
Domainex appoints Timo Veromaa as Executive Chairman
Cambridge, UK, 30th March 2017 / Sciad Newswire / Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce that Dr Timo Veromaa has been appointed Executive Chairman with immediate effect. His appointment expands and strengthens the existing Board and Executive Management Team; Dr Veromaa will have a pivotal role in leading the organisation through…
-
The RSA Group appoints Andy Smith as Consultant in Singapore
The RSA Group, a leading Life Sciences executive search firm, is pleased to announce the appointment of Andy Smith in the firm’s Singapore office.